Semaglutide vs Retatrutide
Compare the research, key figures and safety notes.
How they differ
Semaglutide activates GLP-1 receptors; retatrutide activates GLP-1, GIP and glucagon receptors. The cited research used weekly subcutaneous formulations with half-lives of several days. Semaglutide has licensed products; retatrutide remains investigational. The retatrutide outcome reference here is the 2023 phase-2 obesity study, not a summary of all subsequent trials or a personal-use schedule.
Side by side
| Measure | Semaglutide | Retatrutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence | A · Human dose research | A · Human dose research |
| Route | Subcutaneous | Subcutaneous |
| Half-life | 168 h | 144 h |
| Typical vial | 3 / 5 / 10 mg | 5 / 10 mg |
| Research amount | 0.25–2.4 mg | 0.5–12 mg |
| Common schedule | Once a week | Once a week |
| Cycle / break | Titrated | No validated self-directed course / — |
| Studied for | Metabolism and weight | Metabolism and weight |
These amounts and schedules are figures discussed in research and community reports, shared for learning — not a recommendation and not medical advice. A step-by-step dosing schedule exists only where a human trial backs it; the evidence tier tells you which.
Decay curves, overlaid
Each line is scaled to that compound's own first dose, so the chart shows how each one builds up over time — not how the compounds' doses compare to one another, which these different molecules share no common unit for.
How they combine
Educational reference on commonly-discussed combinations, not medical advice. Combining compounds can change how each behaves — read this as a prompt to research, not a clearance.